Yu-Ling Lin

Yu-Ling Lin

Auto-generated profile, based on publicly available information

Yu-Ling Lin

Department of Nephrology, Hsinchu Cathay General Hospital, Hsinchu 300, Taiwan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YLYu-Ling Lin
Yu-Ling Lin
SLSheng-Hsiang Lin
Sheng-Hsiang Lin
HWHsi-Hao Wang
Hsi-Hao Wang
WHWan-Chia Hsu
Wan-Chia Hsu
SHShih-Yuan Hung
Shih-Yuan Hung
YLYi-Che Lee
Yi-Che Lee
Background: Recent evidence supports the protective role of metformin on kidney function in patients with type 2 diabetes mellitus. However, its potential to prevent new-onset chronic kidney disease (CKD) in patients with type 2 diabetes mellitus with normal renal function remains unclear. Therefore, this study aimed to investigate whether metformin could prevent the development of new-onset CKD in such patients. Methods: This retrospective, observational, multicenter cohort study included 316,693 patients with type 2 diabetes mellitus. After matching using the inverse probability of treatment weighting, 9109 metformin users and 1221 nonusers were analyzed. The primary outcomes were an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2, urinary albumin-to-creatinine ratio of ≥30 mg/g, and a composite outcome defined as new-onset CKD. Results: The multivariable Cox survival model showed that metformin users had significantly better renal outcomes, with a notably lower risk of sustained eGFR of <60 mL/min/1.73 m2 (hazard ratio (HR), 0.71; 95% confidence interval (CI), 0.56–0.90) and new CKD onset (HR, 0.78; 95% CI, 0.65–0.94). Conclusions: Metformin plays a key role in delaying renal events in individuals with type 2 diabetes mellitus and in those with initially normal renal function.

13 March 2024 in Journal of Renal Nutrition
Verified
Journal Article
Open access
YLYu-Ling Lin
Yu-Ling Lin
YLYi-Che Lee
Yi-Che Lee
CLChih-Chung Lee
Chih-Chung Lee
MWMei-Hsuan Wu
Mei-Hsuan Wu
Objectives: Low plasma folate levels have been reported in patients undergoing hemodialysis and peritoneal dialysis (PD) in clinical studies. However, folate transport has never been mentioned as a factor contributing to low plasma folate levels in patients undergoing PD. The peritoneal equilibrium test (PET) assesses the plasma creatinine level and glucose transport abilities. This study aimed to evaluate the association between plasma folate levels and folate transport during PD based on PET grades. Methods: This study recruited 50 patients who underwent PD for >= 3 months and were categorized according to PET grades. Data regarding plasma folate levels and dialysate folate were collected. The primary outcomes were the relationship between the PET grade and plasma folate level and between the PET grade and dialysate-to-plasma folate concentration ratio (D/P folate). Furthermore, the difference in the plasma folate level and D/P folate between men and women was assessed. Results: The plasma folate level and the D/P folate significantly differed among the 4 PET groups (both P < .001). PET grade was significantly negatively correlated with plasma folate levels (r =-0.56, P < .001) and positively correlated with D/P folate (r = 0.686, P < .001). In subgroup analysis, neither the plasma folate level nor the D/P folate significantly differed between men and women. Conclusions: Our study provides clinical evidence that the PET grade is associated with the plasma folate level and D/P folate, regardless of sex. Larger cohort studies are warranted to assess the importance of folate supplementation during PD based on PET grades.

12 August 2025 in Life
Verified
Journal Article
Open access
PDF file
WWWei-Jie Wang
Wei-Jie Wang
YLYu-Ling Lin
Yu-Ling Lin
Ta-Chen SuTa-Chen Su
Ta-Chen Su
CWChi-Kang Wang
Chi-Kang Wang
CLChien Yu Lin
Chien Yu Lin
Purpose: Per- and polyfluoroalkyl substances (PFAS) comprise a class of man-made compounds widely utilized in manufacturing everyday consumer products. Experimental studies indicate that PFAS may interfere with iron regulation by hindering absorption or inducing oxidative stress. Nonetheless, epidemiological studies examining the association between PFAS exposure and a broad spectrum of iron-related biomarkers remain scarce. Approach and Results: In this study, data from the 2013–2018 National Health and Nutrition Examination Survey (NHANES) were analyzed, which included 5050 adults aged 18 and older. The relationships between six PFAS compounds, oral iron intake, and a comprehensive set of markers of iron homeostasis, including serum iron, unsaturated iron-binding capacity (UIBC), total iron-binding capacity (TIBC), transferrin saturation, ferritin, and transferrin receptor levels, were examined. Our findings revealed a negative association between both individual and total PFAS (sum of six PFAS) levels and oral iron intake. Additionally, serum iron and transferrin saturation levels exhibited significant positive correlations with all PFAS compounds, whereas ferritin was positively correlated with all PFAS compounds except n-perfluorooctanoic acid (n-PFOA). UIBC and transferrin receptor showed significant negative correlations with all PFAS compounds, while TIBC was significantly negatively correlated with n-perfluorooctane sulfonic acid (n-PFOS), perfluoromethylheptane sulfonic acid isomers (sm-PFOS), perfluorohexane sulfonic acid (PFHxS), and the total PFAS. Conclusions: Higher PFAS exposure was associated with altered iron status biomarkers While this cross-sectional study cannot establish causality, the observed associations raise the possibility that PFAS exposure may influence iron absorption. These findings emphasize the need for additional research into the potential impact of PFAS exposure on iron homeostasis.

1 January 2019
Verified
Closed access
YLYu-Ling Lin
Yu-Ling Lin
CLChaou-Shune Lin
Chaou-Shune Lin